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Cigarette Smoking and Response  
to Antimalarials in Cutaneous Lupus 
Erythematosus Patients: Evolution  
of a Dogma
Jan Dutz1 and Victoria P. Werth2,3
Antimalarial agents ameliorate disease in more than half of patients with 
cutaneous lupus erythematosus (CLE), regardless of smoking status. The 
major determinant of responsiveness appears to be severity: more extensive 
CLE and CLE in the setting of systemic lupus erythematosus (SLE) respond 
less well to antimalarial therapy. Prospective studies are needed to deter-
mine whether antimalarials are more likely to benefit patients—smokers 
and nonsmokers—who have milder cutaneous lupus. Agreement on a single, 
validated disease severity measure for CLE would permit comparisons among 
studies and thereby foster progress in the field.
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Factors that influence response  
to antimalarials
Discontinuing antimalarial therapy 
in patients with SLE can lead to flares 
in cutaneous and systemic symptoms 
(Canadian Hydroxychloroquine Study 
Group, 1991). As reported by Wahie 
et al. in this issue, however, many 
patients with CLE do not respond 
to antimalarials. Factors previously 
associated with refractory CLE have 
included cigarette smoking and the 
presence of generalized cutaneous 
disease (Jewell and McCauliffe, 2000; 
Moghadam-Kia et al., 2009; Rahman 
et al., 1998).
cigarette smoking and disease severity
In their analysis of newly treated 
patients with discoid lupus erythema-
tosus (DLE), Wahie et al. (this issue, 
2011) note that, although patients 
with DLE are frequent smokers, 
smoking status does not increase the 
rate of antimalarial failure indepen-
dently of other risk factors. The lack 
of an independent effect of smoking 
in a relatively large cohort challenges 
the dermatologic dogma that smoking 
diminishes patients’ responses to anti-
malarial therapy.
How did this notion arise? Rahman 
et al. (1998) first reported that patients 
with cutaneous lupus responded less 
well to antimalarial treatment if they 
were current smokers. Jewell and 
McCauliffe (2000) also reported sig-
nificant differences in responses to 
antimalarials (40%) in smokers com-
pared with nonsmokers (90%) in a 
retrospective study of 61 patients 
from a dermatology clinic. Both were 
relatively small retrospective studies 
that did not control for multiple vari-
ables, and these studies lent support 
to a common “bedside” observation. 
In contrast, Lardet et al. (2004) found 
no independent effect of smoking 
on responses of skin disease to anti-
malarials in a prospective study, but 
their patient numbers were small, and 
the study encompassed several forms 
of skin disease, increasing the like-
lihood of type II (false-negative) error.
Wahie et al. (2011) report that ini-
tial disease severity and the presence 
of systemic disease significantly affect 
patients’ responses to antimalarials. 
Given that smoking is a risk factor for 
the development of cutaneous lupus 
(Gallego et al., 1999; Koskenmies 
et al., 2008) and that it is associated 
with more severe cutaneous disease 
(Piette et al., 2011; Turchin et al., 
2009), it is plausible that previously 
reported associations of smoking 
with poor responses to antimalarial 
treatment arose from confounders—
specifically, severity of disease at the 
onset of treatment and the presence of 
systemic disease. Consistent with this 
model, a recent study demonstrated 
that current smokers respond better 
to antimalarial-only therapy than do 
nonsmokers (Piette et al., 2011). Of 
those not responding to antimalarials 
and requiring additional therapies, 
smokers were less likely to respond to 
treatment, supporting the idea that a 
subset of smokers are therapeutically 
more resistant to all therapies (Piette 
et al., 2011). This evolution in our 
understanding is further supported by 
the observation that smoking does not 
affect plasma levels of hydroxychlo-
roquine (HCQ) (Leroux et al., 2007); 
in addition, it points out the potential 
pitfalls of bedside observation, retro-
spective studies, and studies that lack 
the statistical power required to assess 
confounding variables.
Genetic factors (no correlation  
with cyP3a4 polymorphisms)
Wahie et al. (2011) examined whether 
the significant variations in responses 
to antimalarial treatment known 
to occur in patients with CLE (and 
confirmed by their observations) 
could be attributable to inherent 
differences in HCQ metabolism by 
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hepatic cytochrome P450 enzymes. 
However, examination of therapeu-
tic effects with polymorphisms of 
CYP3A4 did not reveal a significant 
correlation. Little is known about such 
genetic factors and how they might 
modulate responses to antimalarial 
therapy. One group, investigating 
functional genetic polymorphisms of 
tumor necrosis factor-α (TNF-α) and 
IL-10 in modulating the effect of anti-
malarials in SLE, reported that patients 
with a genotype favoring low IL-10 
and high TNF-α levels were the best 
responders to therapy (Lopez et al., 
2006). It remains to be determined 
whether these genotypic markers can 
provide information beyond what is 
gained from clinical phenotyping. 
Furthermore, the role of metabo lizing 
enzymes might be best assessed in 
future studies by documenting serum 
or blood concentrations of HCQ.
Dosing
Plasma HCQ concentration was 
reported to be a negative predictor 
of SLE disease exacerbation during 
a 6-month follow-up of 120 patients 
(Costedoat-Chalumeau et al., 2006). 
Blood HCQ levels have been found 
to correlate with concentrations of 
active metabolites, and thus mea-
surement of HCQ levels alone is a 
reasonable approach to evaluate 
effective drug concentration. It takes 
6 months to achieve steady state, 
and correlations have been made 
between blood steady-state concen-
trations and therapeutic effectiveness 
(Tett et al., 1993). Of interest, there 
is significant variability in the bio-
availability (ranging from 0.3 to 1.0) 
of an oral dose of HCQ, as well as a 
twofold range for clearance of HCQ. 
These variations have suggested that 
using a target concentration of HCQ 
would be reasonable (Carmichael 
et al., 2003). One study suggested 
that a threshold value of 1,000 ng/ml 
provided the best trade-off between 
sensitivity and specificity, as well as a 
high predictive value for SLE exacer-
bations (Costedoat-Chalumeau et al., 
2006). Clearly, more CLE studies are 
needed to be certain of the appropri-
ate approach. Measurement of HCQ 
levels would also identify noncompli-
ant patients, who account for 5–10% 
of the total (Costedoat-Chalumeau et 
al., 2007). In summary, just as there is 
a heterogeneity in clinical response, it 
is clear that there is heterogeneity in 
the blood levels achieved by patients 
who take HCQ and that measuring 
HCQ levels would facilitate optimal 
dosing for patients with a drug that has 
an excellent therapeutic/safety ratio in 
treating CLE. Further genetic studies 
may help identify the causes for the 
differences in the doses required for 
therapeutic effects.
Design of studies
When we have a validated disease 
severity measure for CLE, we should 
be able to design useful prospec-
tive studies for the reasons outlined 
below. All retrospective studies 
include risks for numerous biases 
such as patient selection and loss to 
follow-up. Patient-selection bias can 
be minimized by admitting all indi-
viduals within a geographical area 
(Yang et al., 2010). It is not clear 
how the patients were selected for 
Wahie and colleagues’ retrospective 
study. There may have been dropouts 
related to lack of response, lack of 
tolerance to treatment, or adequate 
therapeutic response. It is difficult to 
capture information for those missing 
individuals.
outcome measurements in cLe
Design of instruments. Finlay (1996) 
has defined the desirable qualities of 
an outcome instrument designed for 
prospective clinical trials. The method 
should be simple enough to use in a 
busy clinical setting and should seg-
regate scores derived from clinical 
observation and scores provided by 
patients. Clinical signs recorded in the 
instrument should be clearly defined, 
proven to be reproducible, and ame-
nable to change upon response to 
treatment. If two signs are highly cor-
related, only one needs to be part of 
the instrument. Recording of area 
of involvement should be based on 
an assessment of the site of involve-
ment rather than the virtually impos-
sible task of determining an accurate 
total percentage involvement. Validity 
testing must be performed, including 
repeatability testing by the same and 
different observers (Finlay, 1996).
Development of a validated disease 
severity instrument for cutaneous 
lupus. An international effort has been 
under way since 2004 to develop a vali-
dated instrument for measuring cuta-
neous lupus severity, the Cutaneous 
Lupus Erythematosus Disease Area and 
Severity Index (CLASI). Initial valida-
tion studies were presented in 2004 
at the First International Conference 
on Cutaneous Lupus Erythematosus, 
held in Dusseldorf, Germany (Albrecht 
et al., 2005). Further consensus was 
obtained in conjunction with the 
European Society of Cutaneous Lupus 
Erythematosus (EUSCLE) study group, 
and details were subsequently published 
(Kuhn et al., 2009). The internation-
al group recognized that consensus 
regarding how to measure CLE severity 
would facilitate development of this 
relatively understudied area, as well as 
avoid the proliferation of severity scores 
that has happened in other clinical 
areas. Subsequent studies extended vali-
dation of the CLASI to include rheuma-
tologic practitioners and their patients. 
They have examined responsiveness in 
the context of therapeutic interventions, 
Clinical Implications
•  Several factors correspond to responses to antimalarials, including the 
number of body areas affected with discoid lupus and the presence of 
systemic lupus erythematosus.
•  Variability in circulating hydroxychloroquine levels among individuals 
receiving the same doses remains unexplained.
•  The ability to measure cutaneous lupus disease severity in a 
reproducible fashion will facilitate prospective studies.
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determined the minimal clinically 
signif icant change in the score, and dem-
onstrated a strong correlation between 
disease severity, as determined by the 
CLASI, and external measures of disease 
severity and quality of life (Albrecht and 
Werth, 2010; Klein et al., 2011). Several 
published studies have demonstrated 
that, with appropriate training, the CLASI 
allows rapid and consistent capture 
of disease severity in cutaneous lupus 
disease activity for all but the most rare 
subsets of CLE and that it is responsive 
to clinical change (Albrecht and Werth, 
2010; Klein et al., 2010). Currently, at 
least five multicenter international tri-
als are relying on the CLASI to evaluate 
skin disease in CLE and SLE patients, as 
either primary or secondary outcome 
measures (ClinicalTrials.gov identi-
fiers NCT01294774, NCT01164917, 
NCT01300208, NCT00708916, and 
NCT00797784). Other studies cur-
rently utilize the CLASI to evaluate 
skin responses in therapeutic trials. 
These studies require capture of the full 
range of cutaneous disease, which can 
include acute, subacute, or chronic 
CLE. Rare manifestations of CLE, includ-
ing lupus panniculitis, bullous SLE, and 
the rare nonerythematous tumid LE, are 
not assessed with the CLASI and are 
unlikely to be the focus of large trials. 
The lipoatrophy from resolved pannicu-
litis is captured in the damage section of 
the CLASI.
Importantly, because approximately 
10% of CLE patients have more than one 
type of cutaneous lesion, an instrument 
must capture the full spectrum of cuta-
neous lupus subsets. Wahie et al. (2010) 
have proposed a DLE-specific instru-
ment, Score of Activity and Damage in 
DLE (SADDLE). Their proposal implies 
the requirement for a different instru-
ment for each subset of CLE and would 
require assessing only patients whose 
exact form of CLE is obvious clinically, 
which is not always the case. Patients 
who have more than one form of CLE 
would need to have only one form of 
their CLE assessed or have disease activ-
ity captured using more than one instru-
ment. Thus, in addition to the focus on 
DLE using a specific assessment tool, 
data using the CLASI score would have 
strengthened the impact of the current 
work by Wahie et al.
The community of cutaneous lupus 
researchers needs a standardized 
method ology. We have seen increasing 
interest in CLE studies, and so this is the 
time to harmonize outcome measures. 
Investigative work in other autoimmune 
disease, including SLE, has suffered 
from a proliferation of disease severity 
measures because outcomes from differ-
ent studies cannot be easily compared. 
Inasmuch as the field of cutaneous 
lupus is still relatively young, we have 
an opportunity through collaboration to 
develop a more uniform approach.
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